Cytokine-release syndrome: differences between high and low doses of OKT3.
Norman
D J
DJ
Oregon Health Sciences University, Portland 97201.
Kimball
J A
JA
Barry
J M
JM
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D016207:Cytokines / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D013577:Syndrome
D000961:Antilymphocyte Serum; D016207:Cytokines; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone; D008775:Methylprednisolone